Peptide LibraryAbaloparatide
Also known as: Tymlos, BA058, PTHrP analog
Abaloparatide (also called Tymlos or BA058) is an FDA-approved PTHrP analog in the PTH1 receptor agonist class. Abaloparatide is a synthetic analog of parathyroid hormone-related protein(1-34), a different endogenous ligand from the parathyroid hormone that teriparatide is derived from, though both act at the PTH1 receptor.
For research use only.
Key Facts
- CAS
- 247062-33-5
- Molecular Weight (MW)
- 3961.6 g/mol
- Half-life
- About 1 hour (Tymlos label)
- FDA status
- Approved
- Evidence level
- FDA Approved
- Human dose established
- Yes
- Administration Route
- Subcutaneous
- Frequency
- Once daily, at about the same time each day
- Last updated
- Nov 7, 2026
- Reviewed
- Nov 7, 2026
- Targets
- PTH1 receptorOsteoblasts
Vendor price snapshot
Each vendor's price is the median price per mg of its own listings; with fewer than 3 vendors there is no typical range. From public vendor listings collected in Oct 2026, so confirm the live price on the vendor site. Peptide Library does not sell peptides.
- Vendors listing this peptide
- 1
- Listed offers
- 1
- Price per mg
- $23.33/mg
Research summary
FDA-approved parathyroid hormone–related peptide analog (Tymlos) for postmenopausal osteoporosis at high fracture risk. Daily 80 mcg subcutaneous injection; treatment typically limited to 2 years.
Research evidence
- Regulatory review (FDA label)1 reviewed source
- Controlled human trialsNone in reviewed sources
- Early or uncontrolled human studiesNone in reviewed sources
- Lab & animal studiesNone in reviewed sources
How it works
Each step shows whether the sources Peptide Library has reviewed include that kind of research. Counts are reviewed sources, not every study ever published. Reviews and programme summaries that describe human use are shown as "reported", not as trials, and registered trials without published results are listed but not counted. A higher step means research has progressed further; it does not mean a compound works better or is safer. Compounds whose evidence has not been reviewed yet show "Not reviewed" instead of a guess.
Peptide Library's Abaloparatide profile summarises 5 cited studies listed in the Science section, the compound's regulatory status, and research-protocol parameters reported for it. It is a research reference, not medical advice.
Abaloparatide dosage evidence
Abaloparatide has an FDA-approved human dosage as Tymlos: 80 mcg once daily by subcutaneous injection into the area around the navel, for postmenopausal women with osteoporosis at high risk for fracture and to increase bone density in men with osteoporosis at high risk. The label says safety and efficacy have not been evaluated beyond 2 years, and use for more than 2 years in a lifetime is not recommended.
| Human dosing established | Yes |
|---|---|
| Studied dose range | 80 mcg once daily |
| Route | Subcutaneous |
| Frequency | Once daily, at about the same time each day |
| Duration studied | Not more than 2 years in a lifetime |
| Half-life | About 1 hour (Tymlos label) |
| Evidence level | FDA Approved |
| Last reviewed | 2026-11-07 |
Research-reported dosing
Doses as studied, one row per regimen. Different trials used different regimens; they are listed separately rather than averaged.
| Study / context | Population | Dose | Route | Frequency | Duration | Outcome studied | Source |
|---|---|---|---|---|---|---|---|
| FDA label — Tymlos, osteoporosisFDA-approved label · FDA prescribing information | Postmenopausal women with osteoporosis at high risk for fracture; men with osteoporosis at high risk for fracture | 80 mcg | Subcutaneous, periumbilical region of the abdomen, rotating the site daily; not intravenous or intramuscular | Once daily | Not more than 2 years in a lifetime | Reduces the risk of vertebral and nonvertebral fractures in postmenopausal women with osteoporosis, and increases bone density in men; the label's 18-month placebo-controlled study enrolled 824 women on 80 mcg and 821 on placebo | TYMLOS (abaloparatide) injection — FDA prescribing information, DailyMed |
Where sources disagree
- Abaloparatide is an analogue of PTHrP(1-34), parathyroid hormone-related peptide. It is not teriparatide, and the two labels set different doses (80 mcg and 20 mcg daily) and different limits on treatment length.
- The label lists osteosarcoma under Warnings and Precautions and says to avoid abaloparatide in people at higher baseline risk, such as those with open growth plates, Paget's disease, bone metastases or skeletal cancer, or prior radiation to the skeleton. It also warns about orthostatic hypotension (the first doses are given where the person can sit or lie down), hypercalcaemia and severe allergic reactions.
- The licensed product is a prefilled pen of 3120 mcg in 1.56 mL that delivers 30 doses of 80 mcg in 40 microlitres each. Research-labelled abaloparatide powder vials are not this product, and the label does not describe them.
Reconstitution
Common research vial sizes: 3 mg.
| Vial | Bacteriostatic water | Concentration | Per 0.01 mL |
|---|---|---|---|
| 3 mg | 1.5 mL | 2 mg/mL | 20 mcg per 0.01 mL |
| 3 mg | 3 mL | 1 mg/mL | 10 mcg per 0.01 mL |
These figures are arithmetic only — they convert a vial and a volume into a concentration. They are not a recommendation to take any dose.
Calculate reconstitution & dose →Handling & administration
- Reconstitution Guide
- Prefilled pen — no reconstitution
- Injection Sites
- AbdomenThighUpper arm (fatty area)
- Concentration Example
- Pre-filled pen: 80 mcg per dose
- Timing Notes
- Inject subcutaneously in abdomen, thigh, or upper arm, preferably at same time each day
- Expected Onset
- Bone density improvements typically seen within 6-12 months
Sequence & molecular data
| Molecular formula | C174H300N56O49 |
|---|---|
| Molecular weight | 3961.6 g/mol |
| CAS number | 247062-33-5 |
| Half-life | ~1–1.7 hours |
| Appearance | Sterile solution in prefilled pen |
| Formulation | Prefilled Pen |
| PubChem CID | 76943386 |
| FDA UNII | AVK0I6HY2U |
| ChEMBL | CHEMBL4084894 |
Identifiers link to the public PubChem, FDA Substance Registration (UNII), ChEMBL and DrugBank records for the same entity.
Science
Mechanism of Action
Abaloparatide is a synthetic analog of parathyroid hormone-related protein(1-34), a different endogenous ligand from the parathyroid hormone that teriparatide is derived from, though both act at the PTH1 receptor. The receptor adopts two conformations, RG and R0; abaloparatide binds the transient RG conformation with relative selectivity, producing shorter receptor occupancy than teriparatide. That shorter signal is thought to favour bone formation over the resorptive response, which is the proposed basis for its differing effect on cortical bone and its lower rate of hypercalcaemia. As with teriparatide, intermittent daily exposure is anabolic while continuous exposure would be catabolic.
Origin
Synthetic PTHrP (1–34) analog.
Targets
Studies
- Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis: A Randomized Clinical Trial
- Clinical effects of teriparatide, abaloparatide, and romosozumab in postmenopausal osteoporosis
- PTH1 receptor agonists for fracture risk: a systematic review and network meta-analysis
- Effectiveness and Safety of Treatments to Prevent Fractures in People With Low Bone Mass or Primary Osteoporosis: A Living Systematic Review and Network Meta-analysis for the American College of Physicians
- Fracture risk reduction and safety by osteoporosis treatment compared with placebo or active comparator in postmenopausal women: systematic review, network meta-analysis, and meta-regression analysis of randomised clinical trials
Research statistics
271 PubMed publications · 27.2% human clinical research · 20 registered trials
Counts of published research through 2026-11-01, not evidence that it works. Publications by year, study types and trials · How publications are counted
Regulatory & research status
Abaloparatide is an FDA-approved product for specific labelled indications. Approval does not extend to the research contexts described on this page, and approved products are prescription medicines.
| FDA status | Approved |
|---|---|
| Availability | Prescription-Only |
| WADA (sport) | Permitted |
| Library classification | FDA-Approved |
How FDA approval, compounding and research-only status differ
Benefits
Abaloparatide side effects
The effects below are drawn from Abaloparatide's prescribing information, which lists the full adverse-reaction data.
Side Effects
- Hypercalcemia
- Dizziness
- Nausea
- Injection-site reactions
- Palpitations
Storage & stability
Lyophilized (freeze-dried) peptide powder is far more stable than the reconstituted solution. Keep sealed vials cold, dry and away from light; long-term storage is typically frozen, with short-term refrigeration for vials in use.
Once reconstituted in bacteriostatic water, keep the solution refrigerated, avoid repeated freeze–thaw cycles and agitation, and label the vial with the reconstitution date and concentration. Discard any solution that turns cloudy or shows particulates.
Degradation rates differ by sequence: peptides containing methionine, cysteine, asparagine or glutamine are more prone to oxidation and deamidation, so shelf life after reconstitution is compound-specific rather than universal.
Read the full guide: how to store peptides before and after reconstitution →
Source: Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharm Res. 2010;27(4):544–575. (PMID 20143256). General guidance for research handling; not product-specific instructions.
Abaloparatide: frequently asked questions
What is Abaloparatide?
FDA-approved parathyroid hormone–related peptide analog (Tymlos) for postmenopausal osteoporosis at high fracture risk. Daily 80 mcg subcutaneous injection; treatment typically limited to 2 years.
How does Abaloparatide work?
Abaloparatide is a synthetic analog of parathyroid hormone-related protein(1-34), a different endogenous ligand from the parathyroid hormone that teriparatide is derived from, though both act at the PTH1 receptor. The receptor adopts two conformations, RG and R0; abaloparatide binds the transient RG conformation with relative selectivity, producing shorter receptor occupancy than teriparatide.
Is Abaloparatide FDA approved?
Yes. Abaloparatide is approved by the FDA, and approved products are prescription medicines. Approval is always for specific indications studied in clinical trials, so an approved status does not mean the compound is approved for every use it is discussed for. Research-chemical material sold under the same name is not the approved product.
What is the half-life of Abaloparatide?
Reported half-life for Abaloparatide is ~1–1.7 hours. Half-life describes how long the compound persists in circulation, not how long any effect lasts, and published figures vary with route of administration, formulation and the population studied.
Is Abaloparatide banned in sport?
Abaloparatide is recorded here as permitted in sport. Anti-doping status is revised annually, so athletes subject to testing should confirm against the current WADA Prohibited List before use.
What peptides are similar to Abaloparatide?
Compounds most often compared with Abaloparatide include Teriparatide, PTH(1-34) Analog (Generic Teriparatide) and Bivalirudin. They are grouped by shared mechanism or research area rather than by equivalence, and their regulatory status and evidence base differ.
References
- FDA label — TymlosExternal reference
- Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis: A Randomized Clinical Trial — JAMA, 2016External reference
- Clinical effects of teriparatide, abaloparatide, and romosozumab in postmenopausal osteoporosis — J Bone Miner Metab, 2025External reference
- PTH1 receptor agonists for fracture risk: a systematic review and network meta-analysis — Osteoporos Int, 2025External reference
- Effectiveness and Safety of Treatments to Prevent Fractures in People With Low Bone Mass or Primary Osteoporosis: A Living Systematic Review and Network Meta-analysis for the American College of Physicians — Ann Intern Med, 2023External reference
- Fracture risk reduction and safety by osteoporosis treatment compared with placebo or active comparator in postmenopausal women: systematic review, network meta-analysis, and meta-regression analysis of randomised clinical trials — BMJ, 2023External reference
Related research, comparisons & guides
Related peptides
Compiled by Peptide Library Editorial · Reviewed Aug 30, 2026 · Updated Nov 7, 2026 · Version 2
This Abaloparatide profile is compiled from published literature (5 cited studies linked above), public regulatory records and chemical registries. It describes what research reports; it is not medical advice, and nothing here is a dosing recommendation for humans. Peptide Library does not sell peptides. Editorial policy · How profiles are compiled · Report an error
Track Abaloparatide research, inventory and reconstitution in the free Peptide Library app. Get the app for iOS or Android →